CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
OKLAHOMA CITY, July 24, 2017 -- Cytovance hosted an unannounced FDA inspection Tuesday, July 11th 2017. The inspector conducted the inspection over an eight day period and focused on Quality Systems. Overall the inspection was very positive and the inspector acknowledged that the site had already identified and taken action on most of the 4 observations. Specifically, Cytovance had taken action to address the facility improvements. All the facility updates are scheduled to be completed during Cytovance’s end of summer shutdown.
“This was a great stepping stone for our quality systems and facility as we get close to our first PAI which we expect later in the year” stated Cytovance’s Vice President of Quality, Maria Lopez. “I am proud of my team and this inspection reiterates Cytovance’s commitment to become a first in class contract manufacturer of our client’s parenteral drug candidates.”
“Cytovance remains committed to providing the highest quality services and therapeutics to our clients,” said Darren Head, president and CEO of Cytovance Biologics, “I know we will work diligently together to complete these actions in a timely manner.”
About Cytovance Biologics
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.
Media Contact Cheryl Tuck 405-319-8309 [email protected]
